Drug Design, Development and Therapy

Dovepress
Taylor & Francis Group

Open Access Full Text Article

RESPONSE TO LETTER

RET Inhibitor SPP86 is a Potential Candidate for the Clinical Treatment of Cutaneous Melanoma [Response to Letter]

Yuli Zhang[1,2], Haidong Liu[1], Kun Wang[3], Juan Zheng[4], Hong Luan[1], Ming Xin[5]

[1]Department of Dermatology, Liaocheng People's Hospital, Liaocheng, Shandong, People's Republic of China; [2]Department of Endocrinology, The Second Hospital of Shandong University, Jinan, Shandong, People's Republic of China; [3]Department of Endocrinology and Metabology, Liaocheng, People's Hospital, Liaocheng, Liaocheng, Shandong, People's Republic of China; [4]Joint Laboratory for Translational Medicine Research, Liaocheng People's Hospital, Liaocheng, Shandong, People's Republic of China; [5]The Key Laboratory of Molecular Pharmacology, Liaocheng People's Hospital, Liaocheng, Shandong, People's Republic of China

Correspondence: Ming Xin, The Key Laboratory of Molecular Pharmacology, Liaocheng People's Hospital, Liaocheng, Shandong, People's Republic of China, Email xinming137@163.com; Hong Luan, Department of Dermatology, Liaocheng People's Hospital, Liaocheng, Shandong, People's Republic of China, Email lcsrmyy@126.com

Dear editors

Thank you very much for your interest in our research and for your valuable feedback. We are grateful for your positive comments and appreciate the constructive suggestions you provided. Your input is essential to further improving our study.

Regarding your suggestion for in vivo experimental validation, we wholeheartedly agree and are actively pursuing related research. In fact, our team has already secured research funding and initiated in vivo experiments using a mouse melanoma model to assess the anti-tumor effects of SPP86. Upon completion of these experiments, we intend to publish the results as a separate paper, and we hope you will look forward to it.

We are also very interested in your suggestion to explore "synthetic lethality as a therapeutic strategy" and the potential of combining SPP86 with PARP1 inhibitors (eg, olaparib). We greatly appreciate this insightful recommendation, and it is an avenue we plan to explore in future studies.

Finally, we acknowledge that clinical treatment for melanoma remains a complex challenge. Our research in this area is ongoing, and we will continue working towards advancing our understanding and contributing to more effective therapeutic options for melanoma treatment.

Disclosure

The authors declare that there are no conflicts of interest in this communication.

Received: 23 February 2025
Accepted: 24 February 2025
Published: 15 March 2025

https://doi.org/10.2147/DDDT.S524526